Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Xofigo (radium-223 chloride) - Important Safety Information from Bayer Healthcare as approved by the HPRA. (Decemeber 2014 Update)
Notice type:
3rd Party Publications
Date:
23/12/2014
Problem Or Issue:
Important Safety Information communication from Bayer Healthcare on temporary drug shortage of Xofigo (radium-223 chloride).
October 2014
1. Important Safety Information communication from Bayer Healthcare on temporary drug shortage of Xofigo (radium-223 chloride). (October 2014)
Decemeber 2014
2.
Important Safety Information communication from Bayer Healthcare for all Healthcare professionals involved in the preparation and administration Xofigo (radium-223 chloride).
« Back
Date Printed: 19/04/2024